AstraZeneca PLC (AZNCF)
| Market Cap | 240.81B |
| Revenue (ttm) | 56.50B |
| Net Income (ttm) | 8.30B |
| Shares Out | n/a |
| EPS (ttm) | 5.31 |
| PE Ratio | 29.03 |
| Forward PE | 15.88 |
| Dividend | 3.13 (2.03%) |
| Ex-Dividend Date | Aug 7, 2025 |
| Volume | 284 |
| Average Volume | 3,278 |
| Open | 152.25 |
| Previous Close | 148.28 |
| Day's Range | 152.25 - 156.78 |
| 52-Week Range | 120.64 - 175.00 |
| Beta | 0.15 |
| RSI | 60.41 |
| Earnings Date | Jul 29, 2025 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B... [Read more]
Financial Performance
In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.
Financial StatementsNews
UK Government, Eli Lilly Partner To Target Obesity Health Gaps
A new program to improve access to weight management services across the U.K. National Health Service (NHS) could benefit several obese patients . The initiative , announced Tuesday, combines governme...
AstraZeneca: Great Portfolio, But Not A Great Price
Melrose boss soars to top of the Footsie pay league
Pascal Soriot, who runs drugs giant AstraZeneca, has slipped to third place in our annual survey, after being replaced by the relatively unknown Dilnot.
Alexion, AstraZeneca Rare Disease reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for Ultomiris for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD) and adults with generalized myasthenia gravis (gMG)
The agreement is a critical step in ensuring adult patients living with NMOSD and gMG have public access to Ultomiris MISSISSAUGA, ON , Aug. 7, 2025 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's ...
SOPHiA GENETICS reaffirms $72M–$76M 2025 revenue guidance as AstraZeneca deal drives BioPharma outlook
EXCLUSIVE: Vivani Prioritizes Semaglutide-Based Implant After Promising Preclinical Data
Vivani Medical Inc. (NASDAQ: VANI) on Tuesday reported results from the LIBERATE-1 Phase 1 study of the exenatide GLP-1 implant NPM-115, representing the first-in-human test of the company's propriet...
SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes
BOSTON and ROLLE, Switzerland , Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced a...
Top global stories this week: HSBC, AstraZeneca, Nissan among notable names
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
Trump demands U.S. drug price cuts, pharma shares slump
AstraZeneca Plc fell as much as 4.2%, and GSK Plc dropped 2.1%
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
European drugmakers fall after Trump raises stakes over US drug price cuts
Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...
Trump threatens NHS with higher drug prices
The US president has told GSK and AstraZeneca to ‘negotiate harder with foreign freeloading nations’
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
3 Of The Best SWANs On My Shopping List
Our picks for today are MercadoLibre, Vulcan Materials, and AstraZeneca, with each providing a mix of value and growth. MercadoLibre is Latin America's leading e-commerce and fintech platform with inc...
Accelerating Impact: AstraZeneca and Revna Biosciences Expand Access to Lung Cancer Treatment in Ghana
ACCRA, Ghana--(BUSINESS WIRE)-- #AfricaHealth--The strategic partnership between AstraZeneca and Revna Biosciences is rapidly transforming the landscape of lung cancer care in Ghana. Since the initial...
Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure
AstraZeneca's CEO said the company has proposed U.S. price cuts to some drugs, while Doximity enters competitive AI scribing market with new free offering.
AstraZeneca PLC (AZN) Q2 2025 Earnings Call Transcript
AstraZeneca CEO: Medical innovation in China is surging
"What we have seen in China is really, a substantial return of scientists from the US, but also from the UK and elsewhere, but not because of policy, simply because they could see opportunities in Chi...
Why AstraZeneca Stock Was Topping the Market on Tuesday
Investors were clearly impressed by the company's second-quarter beats, especially the one on the bottom line.